UBS Group’s Lantern Pharma LTRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $77.9K | Sell |
24,653
-3,438
| -12% | -$10.9K | ﹤0.01% | 6163 |
|
|
2025
Q1 | $99.4K | Buy |
28,091
+407
| +1% | +$1.44K | ﹤0.01% | 5787 |
|
|
2024
Q4 | $88.3K | Buy |
27,684
+813
| +3% | +$2.59K | ﹤0.01% | 5739 |
|
|
2024
Q3 | $98.6K | Buy |
26,871
+1,371
| +5% | +$5.03K | ﹤0.01% | 5193 |
|
|
2024
Q2 | $119K | Hold |
25,500
| – | – | ﹤0.01% | 4934 |
|
|
2024
Q1 | $224K | Sell |
25,500
-458
| -2% | -$4.03K | ﹤0.01% | 4636 |
|
|
2023
Q4 | $111K | Sell |
25,958
-1,042
| -4% | -$4.46K | ﹤0.01% | 4927 |
|
|
2023
Q3 | $92.1K | Hold |
27,000
| – | – | ﹤0.01% | 4770 |
|
|
2023
Q2 | $152K | Hold |
27,000
| – | – | ﹤0.01% | 4633 |
|
|
2023
Q1 | $130K | Buy |
27,000
+12,159
| +82% | +$58.7K | ﹤0.01% | 4652 |
|
|
2022
Q4 | $89.6K | Buy |
14,841
+2,841
| +24% | +$17.2K | ﹤0.01% | 5079 |
|
|
2022
Q3 | $57K | Sell |
12,000
-50
| -0.4% | -$238 | ﹤0.01% | 5152 |
|
|
2022
Q2 | $69K | Sell |
12,050
-1,886
| -14% | -$10.8K | ﹤0.01% | 4690 |
|
|
2022
Q1 | $100K | Buy |
13,936
+826
| +6% | +$5.93K | ﹤0.01% | 4912 |
|
|
2021
Q4 | $105K | Buy |
13,110
+5,433
| +71% | +$43.5K | ﹤0.01% | 5205 |
|
|
2021
Q3 | $86K | Sell |
7,677
-567
| -7% | -$6.35K | ﹤0.01% | 4854 |
|
|
2021
Q2 | $121K | Buy |
8,244
+6,078
| +281% | +$89.2K | ﹤0.01% | 4705 |
|
|
2021
Q1 | $39K | Buy |
+2,166
| New | +$39K | ﹤0.01% | 5775 |
|
|
2020
Q4 | – | Sell |
-112
| Closed | -$2K | – | 7504 |
|
|
2020
Q3 | $2K | Sell |
112
-1,421
| -93% | -$25.4K | ﹤0.01% | 6782 |
|
|
2020
Q2 | $19K | Buy |
+1,533
| New | +$19K | ﹤0.01% | 5743 |
|